{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "wsmg:health-sciences/medicine/gastroenterology/gi-002",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:52:30.000Z",
    "modified": "2026-01-13T13:34:00.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "quality-agent"
    ],
    "confidence": 0.96,
    "status": "validated",
    "language": "en",
    "licenses": ["CC-BY-4.0"]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/gastroenterology",
    "subdomain": "esophageal-disorders",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "high",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Barrett Esophagus",
    "summary": "Barrett esophagus (BE) is a premalignant condition where chronic GERD causes replacement of normal squamous esophageal epithelium with specialized intestinal-type columnar epithelium (intestinal metaplasia). It is the primary risk factor for esophageal adenocarcinoma and requires surveillance endoscopy to detect dysplasia.",
    "key_points": [
      "Definition: Intestinal metaplasia of esophagus with goblet cells on histology",
      "GERD is primary risk factor; other risks: obesity, male, Caucasian, age >50",
      "Salmon-colored mucosa extending above GE junction on endoscopy",
      "Annual adenocarcinoma risk: 0.5% for non-dysplastic BE",
      "Surveillance intervals based on dysplasia grade: no dysplasia q3-5y, LGD q6-12m, HGD treat",
      "Treatment of dysplasia: Radiofrequency ablation (RFA) or endoscopic mucosal resection"
    ],
    "statement": "Barrett esophagus represents the metaplastic replacement of esophageal squamous epithelium with intestinal columnar epithelium due to chronic acid exposure, conferring increased risk of esophageal adenocarcinoma and requiring endoscopic surveillance and intervention for dysplasia.",
    "explanation": {
      "intuition": "Think of Barrett's as the esophagus 'adapting' to chronic acid exposure by replacing its normal lining (squamous, like skin) with a lining more resistant to acid (intestinal, like the stomach/intestine). Unfortunately, this adaptation comes at a cost - the new lining can accumulate mutations leading to cancer over time.",
      "key_insight": "The presence of GOBLET CELLS (intestinal-type cells that produce mucus) is REQUIRED for diagnosis - columnar epithelium without goblet cells is NOT Barrett's. This histologic confirmation is essential because the cancer risk applies only to true intestinal metaplasia.",
      "technical_details": "The metaplasia-dysplasia-carcinoma sequence takes years. Non-dysplastic BE → Low-grade dysplasia (LGD) → High-grade dysplasia (HGD) → Adenocarcinoma. CDX2, MUC2, and CK20 immunostaining can confirm intestinal differentiation. Prague C&M criteria describe circumferential (C) and maximal (M) extent."
    },
    "definitions_glossary": {
      "Barrett_esophagus": "Metaplastic replacement of squamous epithelium with intestinal-type columnar epithelium containing goblet cells",
      "intestinal_metaplasia": "Replacement of native tissue with intestinal-type epithelium including goblet cells",
      "goblet_cell": "Mucus-secreting cell characteristic of intestinal epithelium; required for BE diagnosis",
      "dysplasia": "Neoplastic epithelium confined within basement membrane; precursor to carcinoma",
      "low_grade_dysplasia": "LGD - mild nuclear atypia and architectural distortion; controversial progression risk",
      "high_grade_dysplasia": "HGD - severe atypia approaching carcinoma; high progression risk",
      "Prague_classification": "Endoscopic classification describing C (circumferential) and M (maximum) extent of BE",
      "salmon_colored_mucosa": "Orange-pink appearance of columnar epithelium vs normal whitish squamous",
      "radiofrequency_ablation": "RFA - thermal ablation of Barrett's epithelium using radiofrequency energy",
      "endoscopic_mucosal_resection": "EMR - removal of superficial mucosal lesions for staging/treatment",
      "esophageal_adenocarcinoma": "Cancer arising from Barrett's epithelium; increasing incidence in Western countries",
      "Seattle_protocol": "Biopsy protocol: 4-quadrant biopsies every 1-2cm of BE segment"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "mechanism": "Chronic gastroesophageal reflux causes mucosal injury and healing with intestinal-type epithelium (more acid-resistant but cancer-prone)",
      "molecular_progression": {
        "metaplasia": "CDX2 expression drives intestinal differentiation",
        "dysplasia": "p53 mutations, aneuploidy, LOH at 9p and 17p",
        "carcinoma": "CDKN2A inactivation, TP53 loss, genomic instability"
      },
      "risk_factors": {
        "major": ["Chronic GERD >5 years", "Male sex (8:1)", "Caucasian race", "Central obesity", "Age >50"],
        "other": ["Smoking", "Family history BE/EAC", "Hiatal hernia"]
      },
      "protective": ["H. pylori infection (paradoxically)", "NSAIDs/aspirin use"]
    },
    "diagnostic_criteria": {
      "endoscopic_findings": [
        "Salmon-colored (orange-pink) columnar mucosa above GE junction",
        "Tongue-like extensions or circumferential involvement",
        "Prague C&M classification to document extent"
      ],
      "histologic_confirmation": [
        "Specialized intestinal metaplasia with goblet cells (REQUIRED)",
        "Biopsies from endoscopically suspected BE",
        "4-quadrant biopsies every 1-2 cm (Seattle protocol)"
      ],
      "classification": {
        "short_segment": "<3 cm (SSBE) - lower cancer risk",
        "long_segment": "≥3 cm (LSBE) - higher cancer risk"
      }
    },
    "differential_diagnosis": [
      "Intestinal metaplasia of cardia (at GE junction only)",
      "Inlet patch (heterotopic gastric mucosa in cervical esophagus)",
      "Esophageal adenocarcinoma",
      "Gastric cardia carcinoma"
    ],
    "treatment_options": {
      "surveillance": {
        "no_dysplasia": "EGD with biopsies every 3-5 years",
        "indefinite_for_dysplasia": "Optimize PPI, repeat EGD in 3-6 months",
        "low_grade_dysplasia": "Confirm with expert pathologist; EGD every 6-12 months or consider ablation",
        "high_grade_dysplasia": "Endoscopic eradication therapy (RFA ± EMR)"
      },
      "endoscopic_therapy": {
        "RFA": "Radiofrequency ablation for flat dysplastic BE; 80-90% complete eradication",
        "EMR": "Endoscopic mucosal resection for nodular lesions; provides staging",
        "ESD": "Endoscopic submucosal dissection for larger lesions",
        "cryotherapy": "Alternative ablative modality"
      },
      "medical_therapy": [
        "PPI therapy (reduces progression risk but doesn't eliminate it)",
        "Continue surveillance even with complete eradication"
      ],
      "surgical": {
        "esophagectomy": "Reserved for T1b (submucosal invasion) or greater"
      }
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Barrett Esophagus"
    },
    "altLabel": [
      {"@language": "en", "@value": "Barrett's esophagus"},
      {"@language": "en", "@value": "Barrett oesophagus"},
      {"@language": "en", "@value": "Columnar-lined esophagus"}
    ],
    "definition": {
      "@language": "en",
      "@value": "A premalignant condition characterized by replacement of esophageal squamous epithelium with specialized intestinal-type columnar epithelium containing goblet cells, resulting from chronic gastroesophageal reflux"
    },
    "notation": "gi-002",
    "scopeNote": {
      "@language": "en",
      "@value": "Covers definition, diagnosis, surveillance, and management of Barrett esophagus and dysplasia"
    }
  },
  "relationships": {
    "skos:broader": [
      {
        "@id": "wsmg:health-sciences/medicine/gastroenterology/esophageal-disorders",
        "skos:prefLabel": "Esophageal Disorders"
      }
    ],
    "skos:narrower": [],
    "skos:related": [
      {
        "@id": "wsmg:health-sciences/medicine/gastroenterology/gi-001",
        "skos:prefLabel": "GERD Definition"
      },
      {
        "@id": "wsmg:health-sciences/medicine/gastroenterology/gi-042",
        "skos:prefLabel": "Esophageal Cancer Staging"
      }
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Barrett's_esophagus"
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "302914006",
      "uri": "http://snomed.info/id/302914006",
      "description": "Barrett esophagus"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "ICD-10-CM",
      "codeValue": "K22.7",
      "uri": "http://hl7.org/fhir/sid/icd-10-cm/K22.7",
      "description": "Barrett's esophagus"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D001471",
      "uri": "http://id.nlm.nih.gov/mesh/D001471",
      "description": "Barrett Esophagus"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Define Barrett esophagus and identify required histologic features",
      "Describe the metaplasia-dysplasia-carcinoma sequence",
      "Apply surveillance intervals based on dysplasia grade",
      "Compare endoscopic treatment modalities (RFA, EMR)",
      "Identify risk factors for Barrett's and esophageal adenocarcinoma"
    ],
    "clinical_pearls": [
      "No goblet cells = NOT Barrett's, regardless of endoscopic appearance",
      "Long-segment BE (≥3cm) has higher cancer risk than short-segment",
      "HGD on biopsy = expert pathologist confirmation + treatment (not just surveillance)",
      "Annual cancer risk in non-dysplastic BE is only 0.5% - counsel appropriately",
      "Continue surveillance even after complete eradication - recurrence possible"
    ],
    "board_yield": "HIGH",
    "estimated_time": "25min",
    "target_audience": [
      "gastroenterology_fellows",
      "internal_medicine_residents",
      "medical_students"
    ],
    "common_misconceptions": [
      "Salmon-colored mucosa = Barrett's - histology with goblet cells required",
      "All BE patients get cancer - annual risk only 0.5%",
      "RFA cures Barrett's permanently - recurrence can occur, surveillance continues"
    ]
  },
  "prerequisites": [
    {
      "@id": "wsmg:health-sciences/medicine/gastroenterology/gi-001",
      "skos:prefLabel": "GERD Definition"
    }
  ],
  "related_concepts": [
    "GERD",
    "intestinal metaplasia",
    "dysplasia",
    "radiofrequency ablation",
    "esophageal adenocarcinoma"
  ],
  "evidence": {
    "citations": [
      {
        "authors": "Shaheen NJ, Falk GW, Iyer PG, Souza RF, et al.",
        "title": "ACG Clinical Guideline: Barrett's Esophagus",
        "journal": "Am J Gastroenterol",
        "year": 2022,
        "volume": "117",
        "pages": "559-587",
        "doi": "10.14309/ajg.0000000000001680"
      }
    ],
    "confidence_rationale": "Based on ACG 2022 guidelines for Barrett's esophagus"
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-13T13:34:00.000Z",
    "sources": [
      {
        "source": "ACG Clinical Guideline: Barrett's Esophagus. Am J Gastroenterol. 2022.",
        "type": "guideline",
        "year": 2022,
        "relevance": "Evidence-based Barrett's management"
      },
      {
        "source": "Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th ed. Elsevier, 2021.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0323609623",
        "relevance": "Comprehensive GI reference"
      }
    ]
  },
  "quality_assessment": {
    "content_quality_score": 0.95,
    "completeness": 0.96,
    "accuracy": 0.96,
    "clarity": 0.94,
    "clinical_relevance": 0.97,
    "last_assessed": "2026-01-13T13:34:00.000Z"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Barrett's_esophagus",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q797444"
}